SiRNA-mediated knockdown of the mTOR inhibitor RTP801 promotes retinal ganglion cell survival and axon elongation by direct and indirect mechanisms

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 2, 2016, Pages 429-443

  Morgan Warren, Peter J ^a   O’Neill, Jenna ^a,b   De Cogan, Felicity ^a   Spivak, Igor ^c   Ashush, Hagit ^c   Kalinski, Hagar ^c   Ahmed, Zubair ^a   Berry, Martin ^a   Feinstein, Elena ^c   Scott, Robert A H ^a,d,e   Logan, Ann ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Neuregenix Ltd   (United Kingdom)

^c QBI Enterprises Ltd   (Israel)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e CITY HOSPITAL   (United Kingdom)

Author keywords

Axon regeneration; Neuroprotection; RNA interference

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR RTP 801; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, RAT; NERVE GROWTH FACTOR; RAPAMYCIN; REPRESSOR PROTEIN; RTP801 PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; NERVE ELONGATION; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA GANGLION CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; AXON; CYTOLOGY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; NERVE CRUSH; NERVE REGENERATION; OPTIC NERVE INJURIES; PHYSIOLOGY; WISTAR RAT;

ANIMALS; AXONS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTRAVITREAL INJECTIONS; MALE; NERVE CRUSH; NERVE GROWTH FACTORS; NERVE REGENERATION; OPTIC NERVE INJURIES; RATS; RATS, WISTAR; REPRESSOR PROTEINS; RETINAL GANGLION CELLS; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84957597463     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17511     Document Type: Article

References (86)

1. Steinsapir KD, Goldberg RA. Traumatic optic neuropathy: an evolving understanding. Am J Ophthalmol. 2011;151:928–933.e2.
2. Wu N, Yin ZQ, Wang Y. Traumatic optic neuropathy therapy: an update of clinical and experimental studies. J Int Med Res. 2008;36:883–889.
3. Yu-Wai-Man P, Griffiths PG. Surgery for traumatic optic neuropathy. Cochrane Database Syst Rev. 2013;6:CD005024.
4. Yu-Wai-Man P, Griffiths PG. Steroids for traumatic optic neuropathy. Cochrane Database Syst Rev. 2013;6:CD006032.
5. Berkelaar M, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci. 1994;14:4368–4374.
6. Ahmed Z, Kalinski H, Berry M, et al. Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis. 2011;2:e173.
7. Vigneswara V, Berry M, Logan A, Ahmed Z. Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats. PLoS One. 2012;7:e53473.
8. Monnier PP, D’Onofrio PM, Magharious M, et al. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells. J Neurosci. 2011;31:10494–10505.
9. Cenni MC, Bonfanti L, Martinou JC, Ratto GM, Strettoi E, Maffei L. Long-term survival of retinal ganglion cells following optic nerve section in adult bcl-2 transgenic mice. Eur J Neurosci. 1996;8:1735–1745.
10. Inoue T, Hosokawa M, Morigiwa K, Ohashi Y, Fukuda Y. Bcl-2 overexpression does not enhance in vivo axonal regeneration of retinal ganglion cells after peripheral nerve transplantation in adult mice. J Neurosci. 2002;22:4468–4477.
11. Malik JM, Shevtsova Z, Bahr M, Kugler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther. 2005;11:373–381.
12. Berry M, Ahmed Z, Lorber B, Douglas M, Logan A. Regeneration of axons in the visual system. Restor Neurol Neurosci. 2008;26:147–174.
13. Tan HB, Zhong YS, Cheng Y, Shen X. Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage. Int J Ophthalmol. 2011;4:652–657.
14. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci. 2006;7:617–627.
15. Lehmann M, Fournier A, Selles-Navarro I, et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci. 1999;19:7537–7547.
16. Ahmed Z, Berry M, Logan A. ROCK inhibition promotes adult retinal ganglion cell neurite outgrowth only in the presence of growth promoting factors. Mol Cell Neurosci. 2009;42:128–133.
17. Mey J, Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res. 1993;602:304–317.
18. Yip HK, So KF. Axonal regeneration of retinal ganglion cells: effect of trophic factors. Prog Retin Eye Res. 2000;19:559–575.
19. Ahmed Z, Aslam M, Lorber B, Suggate EL, Berry M, Logan A. Optic nerve and vitreal inflammation are both RGC neuroprotective but only the latter is RGC axogenic. Neurobiol Dis. 2010;37:441–454.
20. Logan A, Ahmed Z, Baird A, Gonzalez AM, Berry M. Neurotrophic factor synergy is required for neuronal survival and disinhibited axon regeneration after CNS injury. Brain. 2006;129:490–502.
21. Muller A, Hauk TG, Fischer D. Astrocyte-derived CNTF switches mature RGCs to a regenerative state following inflammatory stimulation. Brain. 2007;130:3308–3320.
22. Leibinger M, Muller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J Neurosci. 2009;29:14334–14341.
23. Vigneswara V, Akpan N, Berry M, Logan A, Troy CM, Ahmed Z. Combined suppression of CASP2 and CASP6 protects retinal ganglion cells from apoptosis and promotes axon regeneration through CNTF-mediated JAK/STAT signalling. Brain. 2014; 137:1656–1675.
24. Lorber B, Berry M, Douglas MR, Nakazawa T, Logan A. Activated retinal glia promote neurite outgrowth of retinal ganglion cells via apolipoprotein E. J Neurosci Res. 2009;87: 2645–2652.
25. Lorber B, Guidi A, Fawcett JW, Martin KR. Activated retinal glia mediated axon regeneration in experimental glaucoma. Neurobiol Dis. 2012;45:243–252.
26. Fischer D, Leibinger M. Promoting optic nerve regeneration. Prog Retin Eye Res. 2012;31:688–701.
27. Moore DL, Blackmore MG, Hu Y, et al. KLF family members regulate intrinsic axon regeneration ability. Science. 2009;326: 298–301.
28. Liu K, Tedeschi A, Park KK, He Z. Neuronal intrinsic mechanisms of axon regeneration. Annu Rev Neurosci. 2011;34:131–152.
29. Park KK, Liu K, Hu Y, Kanter JL, He Z. PTEN/mTOR and axon regeneration. Exp Neurol. 2010;223:45–50.
30. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307–318.
31. Park KK, Liu K, Hu Y, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science. 2008;322:963–966.
32. Zhou FQ, Snider WD. Cell biology. GSK-3beta and microtubule assembly in axons. Science. 2005;308:211–214.
33. Abe N, Borson SH, Gambello MJ, Wang F, Cavalli V. Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J Biol Chem. 2010;285:28034–28043.
34. Christie KJ, Webber CA, Martinez JA, Singh B, Zochodne DW. PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. J Neurosci. 2010;30:9306–9315.
35. Liu K, Lu Y, Lee JK, et al. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci. 2010;13:1075–1081.
36. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
37. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/ TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–2904.
38. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001;15:1383–1392.
39. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115: 577–590.
40. Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 2005;280: 9769–9772.
41. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008; 22:239–251.
42. Malagelada C, Lopez-Toledano MA, Willett RT, Jin ZH, Shelanski ML, Greene LA. RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J Neurosci. 2011;31:3186–3196.
43. Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol. 2002;22:2283–2293.
44. del Olmo-Aguado S, Nunez-Alvarez C, Ji D, Manso AG, Osborne NN. RTP801 immunoreactivity in retinal ganglion cells and its down-regulation in cultured cells protect them from light and cobalt chloride. Brain Res Bull. 2013;98:132–144.
45. Brafman A, Mett I, Shafir M, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci. 2004;45:3796–3805.
46. Nguyen QD, Schachar RA, Nduaka CI, et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci. 2012;53:7666–7674.
47. Rittenhouse KD, Johnson TR, Vicini P, et al. RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP 801. Invest Ophthalmol Vis Sci. 2014;55:1232–1240.
48. Nguyen QD, Schachar RA, Nduaka CI, et al. Phase 1 doseescalation study of a siRNA targeting the RTP801 gene in agerelated macular degeneration patients. Eye (Lond). 2012;26: 1099–1105.
49. Lee DU, Huang W, Rittenhouse KD, Jessen B. Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. J Ocul Pharmacol Ther. 2012; 28:222–230.
50. Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology. 2012;119:1867–1873.
51. Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31:2705–2716.
52. Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2004; 101:14883–14888.
53. Berry M, Carlile J, Hunter A, Tsang W, Rosenstiel P, Sievers J. Optic nerve regeneration after intravitreal peripheral nerve implants: trajectories of axons regrowing through the optic chiasm into the optic tracts. J Neurocytol. 1999;28:721–741.
54. Vigneswara V, Berry M, Logan A, Ahmed Z. Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury. Invest Ophthalmol Vis Sci. 2013;54:2624–2633.
55. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. Invest Ophthalmol Vis Sci. 2013; 54:7544–7556.
56. Mead B, Thompson A, Scheven BA, Logan A, Berry M, Leadbeater W. Comparative evaluation of methods for estimating retinal ganglion cell loss in retinal sections and wholemounts. PLoS One. 2014;9:e110612.
57. Schaden H, Stuermer CA, Bahr M. GAP-43 immunoreactivity and axon regeneration in retinal ganglion cells of the rat. J Neurobiol. 1994;25:1570–1578.
58. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37:417–429.
59. Suggate EL, Ahmed Z, Read ML, et al. Optimisation of siRNAmediated RhoA silencing in neuronal cultures. Mol Cell Neurosci. 2009;40:451–462.
60. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and targetindependent angiogenesis suppression by siRNA via TLR 3. Nature. 2008;452:591–597.
61. Forsbach A, Nemorin JG, Montino C, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8- dependent immune responses. J Immunol. 2008;180:3729–3738.
62. Riechenbach A, Wolburg H. Astrocytes and ependymal glia. In: Keffenmann H, Ransom BR, eds. Neuroglia. Oxford, UK: Oxford University Press; 2013.
63. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and effects on microglia. Glia. 2001;33: 131–142.
64. Sun F, Park KK, Belin S, et al. Sustained axon regeneration induced by co-deletion of PTEN and SOCS 3. Nature. 2011; 480:372–375.
65. de Lima S, Koriyama Y, Kurimoto T, et al. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc Natl Acad Sci U S A. 2012;109:9149–9154.
66. Aguirre A, Maturana CJ, Harcha PA, Saez JC. Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediators Inflamm. 2013;2013:893521.
67. Lorber B, Berry M, Logan A. Different factors promote axonal regeneration of adult rat retinal ganglion cells after lens injury and intravitreal peripheral nerve grafting. J Neurosci Res. 2008;86:894–903.
68. Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson’s disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci. 2006;26:9996–10005.
69. Read ML, Mir S, Spice R, et al. Profiling RNA interference (RNAi)-mediated toxicity in neural cultures for effective short interfering RNA design. J Gene Med. 2009;11:523–534.
70. Duan X, Qiao M, Bei F, Kim IJ, He Z, Sanes JR. Subtype-specific regeneration of retinal ganglion cells following axotomy: effects of osteopontin and mTOR signaling. Neuron. 2015; 85:1244–1256.
71. Goldberg JL, Espinosa JS, Xu Y, Davidson N, Kovacs GT, Barres BA. Retinal ganglion cells do not extend axons by default: promotion by neurotrophic signaling and electrical activity. Neuron. 2002;33:689–702.
72. Joos KM, Li C, Sappington RM. Morphometric changes in the rat optic nerve following short-term intermittent elevations in intraocular pressure. Invest Ophthalmol Vis Sci. 2010;51: 6431–6440.
73. Leibinger M, Andreadaki A, Fischer D. Role of mTOR in neuroprotection and axon regeneration after inflammatory stimulation. Neurobiol Dis. 2012;46:314–324.
74. Cui Q, Lu Q, So KF, Yip HK. CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest Ophthalmol Vis Sci. 1999;40: 760–766.
75. Harada T, Harada C, Kohsaka S, et al. Microglia-Muller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci. 2002;22:9228–9236.
76. Taylor S, Srinivasan B, Wordinger RJ, Roque RS. Glutamate stimulates neurotrophin expression in cultured Muller cells. Brain Res Mol Brain Res. 2003;111:189–197.
77. Seki M, Tanaka T, Sakai Y, et al. Muller cells as a source of brain-derived neurotrophic factor in the retina: noradrenaline upregulates brain-derived neurotrophic factor levels in cultured rat Muller cells. Neurochem Res. 2005;30:1163–1170.
78. Pernet V, Schwab ME. Lost in the jungle: new hurdles for optic nerve axon regeneration. Trends Neurosci. 2014;37:381–387.
79. Chong RS, Martin KR. Glial cell interactions and glaucoma. Curr Opin Ophthalmol. 2015;26:73–77.
80. Qu J, Jakobs TC. The time course of gene expression during reactive gliosis in the optic nerve. PLoS One. 2013;8:e67094.
81. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–137.
82. Tang Z, Baykal AT, Gao H, et al. mTor is a signaling hub in cell survival: a mass-spectrometry-based proteomics investigation. J Proteome Res. 2014;13:2433–2444.
83. Dill J, Wang H, Zhou F, Li S. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci. 2008;28:8914–8928.
84. Liz MA, Mar FM, Santos TE, et al. Neuronal deletion of GSK3beta increases microtubule speed in the growth cone and enhances axon regeneration via CRMP-2 and independently of MAP1B and CLASP 2. BMC Biol. 2014;12:47.
85. Seira O, Del Rio JA. Glycogen synthase kinase 3 beta (GSK3beta) at the tip of neuronal development and regeneration. Mol Neurobiol. 2014;49:931–944.
86. Guzman-Aranguez A, Loma P, Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol. 2013;170:730–747.